Brief: Renovorx Engages Oklahoma University (Ou) Health As First Clinical Site
21/12/2023 14:49
Dec 21 (Reuters) - RenovoRx Inc RNXT.O :
* RENOVORX ENGAGES OKLAHOMA UNIVERSITY (OU) HEALTH AS FIRST
CLINICAL SITE IN PREPARATION FOR THE PIVOTAL PHASE III COUGAR
CLINICAL TRIAL IN BILE DUCT CANCER
Source text for Eikon: ID:nBwc4MKH1a
Further company coverage: RNXT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on RenovoRx
See all newsBrief: RenovoRx Gets FDA Orphan Drug Designation For Oxaliplatin To Treat Pancreatic Cancer
RenovoRx Q1 revenue rises as number of active cancer centers increase
RenovoRx 2025 net loss widens on higher operating expenses
Brief: RenovoRx FY Net Income USD -11.168 Million
U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies